Teitur Trophics is pleased to announce the initiation of its first clinical trial in patients with Parkinson’s disease. The study marks an important milestone in the company’s ongoing Phase I clinical development program.

The trial is being conducted in the Netherlands in collaboration with the Centre for Human Drug Research (CHDR) and is now actively enrolling participants. Further details about the study are available here: https://lnkd.in/espdvMpa

The objective of the study is to evaluate the effects of Teitur Trophics’ lead clinical candidate, TT-P34, a novel therapeutic approach designed to protect and restore neuronal function. This milestone represents a significant step forward in Teitur Trophics’ mission to develop disease-modifying therapies for neurodegenerative disorders.

By targeting the underlying biological mechanisms of Parkinson’s disease rather than solely addressing symptoms, Teitur Trophics aims to advance the development of novel treatment options for patients and families affected by this condition.

Teitur Trophics would like to thank its dedicated team, its clinical partner CHDR, and its advisors for their expertise, commitment, and continued support in reaching this important achievement.